Welcome to NewsHome

This website is intended for journalists or healthcare professionals outside the US/UK who are interested in media information from Boehringer Ingelheim. Please choose an option below:

I am a journalist or HCP outside the US/UKI am a journalist or HCP in the US/UKI am not a journalist or HCP
 
Rating:00
view video larger
Related links:
Nintedanib Backgrounder Thumbnail
Nintedanib Backgrounder
Read more >
ErbB Family Blockade Infographic thumb
ErbB family Blockade and Afatinib Infographic
Read more >

Could new cancer targets change the outlook for personalised medicine?

Interview with Kathleen Pritchard,
MD, FRCPC
Toronto Sunnybrook Regional Cancer Center,
Toronto, Ontario, Canada

01.12.2010

Nixon's declaration of the war on cancer in 1971 was almost 40 years ago and I guess we haven't beaten cancer completely yet. What we have done in breast cancer since 1971 is reduce the amount of surgery - we have breast conserving surgery now; we have effective chemotherapy and hormonal therapy to prevent recurrence after surgery.

And now we have moved into an era where we have targeted or biologic drugs, such as Herceptin against the HER2 marker in breast cancer. But only about 20% of women with breast cancer have that marker and Herceptin doesn't work in everyone. So now we are looking at a variety of small molecules, which may go on to other pathways or other markers in breast cancer and help to improve the outcome with those types of cancer also.

VIEW IN FULL ADD TO SELECTION DOWNLOAD DOWNLOAD TRANSCRIPT